RxDoctor Payments Data

Juan Brito Villalon, MD

General Practice · West Miami, FLNPI 1184163974

Payments from drug & device makers

$495in general payments, 2019–2025

Across 26 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$122
  • Novo Nordisk$76
  • Sumitomo Pharma America, Inc.$74
  • Astellas Pharma US Inc$43
  • AstraZeneca$40
  • Gilead$37
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$495 in reported general payments places this provider in the 65th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$5,783
Medicare patients
13
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide337$322,253
EliquisApixaban174$139,607
JardianceEmpagliflozin140$121,195
JanuviaSitagliptin Phosphate156$114,476
FarxigaDapagliflozin Propanediol132$94,797
LinzessLinaclotide99$67,143
EntrestoSacubitril/Valsartan60$62,053
MounjaroTirzepatide58$60,756
XareltoRivaroxaban35$35,997
MyrbetriqMirabegron60$35,764
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$31,362
Breo ElliptaFluticasone/Vilanterol61$25,551
RybelsusSemaglutide19$25,218
ProliaDenosumab14$23,925
RestasisCyclosporine25$18,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$76$347,471356 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$36$140,957174 claims
MerckJanuvia$15$114,476156 claims
AstraZenecaFarxiga, Symbicort$40$100,708154 claims
Lilly USA, LLCMounjaro, Trulicity$14$73,18871 claims
Johnson & JohnsonXarelto$122$35,99735 claims
Astellas Pharma US IncMyrbetriq$43$35,76460 claims
BayerKerendia$22$14,58319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,901 general practice providers in Florida.

Other general practice in West Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →